Which has higher earnings & valuation, OCGN or MRNA?

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 99.79 -$67.85M -$0.24 N/A Moderna $1.94B 10.01 -$2.82B -$8.15 N/A

Is OCGN or MRNA more profitable?

Moderna has a net margin of -143.55% compared to Ocugen's net margin of -1,192.18%. Moderna's return on equity of -26.64% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen -1,192.18% -127,987.80% -135.48% Moderna -143.55% -26.64% -19.32%

Does the media prefer OCGN or MRNA?

In the previous week, Moderna had 23 more articles in the media than Ocugen. MarketBeat recorded 28 mentions for Moderna and 5 mentions for Ocugen. Moderna's average media sentiment score of 0.46 beat Ocugen's score of 0.44 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 10 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral

Which has better valuation & earnings, OCGN or PFE?

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 99.79 -$67.85M -$0.24 N/A Pfizer $62.58B 2.31 $7.77B $1.31 19.36

Is OCGN or PFE more profitable?

Pfizer has a net margin of 11.83% compared to Ocugen's net margin of -1,192.18%. Pfizer's return on equity of 19.44% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen -1,192.18% -127,987.80% -135.48% Pfizer 11.83% 19.44% 8.41%

Does the media favor OCGN or PFE?

In the previous week, Pfizer had 76 more articles in the media than Ocugen. MarketBeat recorded 81 mentions for Pfizer and 5 mentions for Ocugen. Pfizer's average media sentiment score of 0.63 beat Ocugen's score of 0.44 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pfizer 34 Very Positive mention(s) 17 Positive mention(s) 13 Neutral mention(s) 10 Negative mention(s) 7 Very Negative mention(s) Positive

Is OCGN or NRIX more profitable?

Nurix Therapeutics has a net margin of -411.37% compared to Ocugen's net margin of -1,192.18%. Nurix Therapeutics' return on equity of -64.21% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen -1,192.18% -127,987.80% -135.48% Nurix Therapeutics -411.37% -64.21% -48.44%

Is OCGN or RAPP more profitable?

Rapport Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Rapport Therapeutics' return on equity of -24.78% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen -1,192.18% -127,987.80% -135.48% Rapport Therapeutics N/A -24.78% -23.44%

Does the media prefer OCGN or RAPP?

In the previous week, Ocugen and Ocugen both had 5 articles in the media. Rapport Therapeutics' average media sentiment score of 0.58 beat Ocugen's score of 0.44 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapport Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ocugen (OCGN) Competitors

$1.30 -0.04 (-2.99%)

Closing price 04:00 PM Eastern

Extended Trading

$1.32 +0.02 (+1.38%)

As of 07:58 PM Eastern

Compare

OCGN vs. MRNA, PFE, LKFT, NRIX, and RAPP

Should you buy Ocugen stock or one of its competitors? MarketBeat compares Ocugen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocugen include Moderna (MRNA), Pfizer (PFE), Lakefront Biotherapeutics American Depositary Shares (LKFT), Nurix Therapeutics (NRIX), and Rapport Therapeutics (RAPP). These companies are all part of the "medical" sector.

How does Ocugen compare to Moderna?

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Ocugen presently has a consensus price target of $9.50, suggesting a potential upside of 630.77%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 27.16%. Given Ocugen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ocugen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Ocugen has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	99.79	-$67.85M	-$0.24	N/A
Moderna	$1.94B	10.01	-$2.82B	-$8.15	N/A

Moderna has a net margin of -143.55% compared to Ocugen's net margin of -1,192.18%. Moderna's return on equity of -26.64% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 23 more articles in the media than Ocugen. MarketBeat recorded 28 mentions for Moderna and 5 mentions for Ocugen. Moderna's average media sentiment score of 0.46 beat Ocugen's score of 0.44 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	10 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral

10.3% of Ocugen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Ocugen and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

How does Ocugen compare to Pfizer?

Ocugen (NASDAQ:OCGN) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Ocugen has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Pfizer has a net margin of 11.83% compared to Ocugen's net margin of -1,192.18%. Pfizer's return on equity of 19.44% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Pfizer	11.83%	19.44%	8.41%

In the previous week, Pfizer had 76 more articles in the media than Ocugen. MarketBeat recorded 81 mentions for Pfizer and 5 mentions for Ocugen. Pfizer's average media sentiment score of 0.63 beat Ocugen's score of 0.44 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	34 Very Positive mention(s)	17 Positive mention(s)	13 Neutral mention(s)	10 Negative mention(s)	7 Very Negative mention(s)	Positive

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	99.79	-$67.85M	-$0.24	N/A
Pfizer	$62.58B	2.31	$7.77B	$1.31	19.36

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 0.6% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ocugen currently has a consensus price target of $9.50, suggesting a potential upside of 630.77%. Pfizer has a consensus price target of $28.82, suggesting a potential upside of 13.64%. Given Ocugen's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocugen is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pfizer	3 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.20

Summary

Pfizer beats Ocugen on 12 of the 17 factors compared between the two stocks.

How does Ocugen compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Ocugen	-1,192.18%	-127,987.80%	-135.48%

In the previous week, Ocugen had 1 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 5 mentions for Ocugen and 4 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.61 beat Ocugen's score of 0.44 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $36.50, suggesting a potential upside of 32.68%. Ocugen has a consensus target price of $9.50, suggesting a potential upside of 630.77%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Ocugen. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.44	$363.05M	-$1.41	N/A
Ocugen	$4.41M	99.79	-$67.85M	-$0.24	N/A

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Ocugen beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 17 factors compared between the two stocks.

How does Ocugen compare to Nurix Therapeutics?

Ocugen (NASDAQ:OCGN) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Ocugen has higher earnings, but lower revenue than Nurix Therapeutics. Ocugen is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	99.79	-$67.85M	-$0.24	N/A
Nurix Therapeutics	$83.98M	19.06	-$264.46M	-$3.16	N/A

Ocugen presently has a consensus target price of $9.50, suggesting a potential upside of 630.77%. Nurix Therapeutics has a consensus target price of $30.46, suggesting a potential upside of 96.78%. Given Ocugen's higher probable upside, equities analysts plainly believe Ocugen is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Nurix Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

10.3% of Ocugen shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Ocugen had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 5 mentions for Ocugen and 1 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.89 beat Ocugen's score of 0.44 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ocugen	Neutral
Nurix Therapeutics	Very Positive

Nurix Therapeutics has a net margin of -411.37% compared to Ocugen's net margin of -1,192.18%. Nurix Therapeutics' return on equity of -64.21% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Ocugen has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

Summary

Nurix Therapeutics beats Ocugen on 10 of the 17 factors compared between the two stocks.

How does Ocugen compare to Rapport Therapeutics?

Ocugen (NASDAQ:OCGN) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Rapport Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Rapport Therapeutics' return on equity of -24.78% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Ocugen has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	99.79	-$67.85M	-$0.24	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Ocugen has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

10.3% of Ocugen shares are owned by institutional investors. 4.0% of Ocugen shares are owned by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ocugen presently has a consensus price target of $9.50, indicating a potential upside of 630.77%. Rapport Therapeutics has a consensus price target of $58.83, indicating a potential upside of 59.01%. Given Ocugen's higher possible upside, research analysts plainly believe Ocugen is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Ocugen and Ocugen both had 5 articles in the media. Rapport Therapeutics' average media sentiment score of 0.58 beat Ocugen's score of 0.44 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapport Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rapport Therapeutics beats Ocugen on 8 of the 15 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCGN vs. The Competition

Export

Metric	Ocugen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$453.62M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-5.42	9.91	18.89	22.53
Price / Sales	99.79	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	-32.50	6.63	9.84	6.72
Net Income	-$67.85M	$24.20M	$3.57B	$337.19M
7 Day Performance	-5.80%	-3.24%	-1.16%	0.48%
1 Month Performance	-27.78%	0.53%	3.85%	5.07%
1 Year Performance	52.65%	47.24%	27.40%	34.25%

Ocugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCGN Ocugen	2.2428 of 5 stars	$1.30 -3.0%	$9.50 +630.8%	+60.1%	$453.62M	$4.41M	N/A	80	News Coverage Analyst Upgrade
MRNA Moderna	1.4946 of 5 stars	$46.88 flat	$35.73 -23.8%	+68.7%	$18.60B	$1.94B	N/A	4,700	Trending News
PFE Pfizer	3.5162 of 5 stars	$25.92 +0.1%	$28.61 +10.4%	+9.0%	$147.62B	$62.58B	19.79	75,000	Trending News Analyst Forecast
LKFT Lakefront Biotherapeutics American Depositary Shares	2.5635 of 5 stars	$27.49 flat	$36.50 +32.8%	-6.6%	$1.81B	$1.26B	N/A	1,310
NRIX Nurix Therapeutics	3.0622 of 5 stars	$17.50 flat	$30.46 +74.1%	+34.8%	$1.81B	$83.98M	N/A	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCGN) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, LKFT, NRIX, and RAPP

How does Ocugen compare to Moderna?

Summary

How does Ocugen compare to Pfizer?

Summary

How does Ocugen compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Ocugen compare to Nurix Therapeutics?

Summary

How does Ocugen compare to Rapport Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocugen (OCGN) Competitors

OCGN vs. MRNA, PFE, LKFT, NRIX, and RAPP

How does Ocugen compare to Moderna?

Do analysts rate OCGN or MRNA?

Which has more volatility & risk, OCGN or MRNA?

Which has higher earnings & valuation, OCGN or MRNA?

Is OCGN or MRNA more profitable?

Does the media prefer OCGN or MRNA?

Do institutionals and insiders have more ownership in OCGN or MRNA?

Summary

How does Ocugen compare to Pfizer?

Which has more volatility & risk, OCGN or PFE?

Is OCGN or PFE more profitable?

Does the media favor OCGN or PFE?

Which has better valuation & earnings, OCGN or PFE?

Do insiders & institutionals hold more shares of OCGN or PFE?

Do analysts prefer OCGN or PFE?

Summary

How does Ocugen compare to Lakefront Biotherapeutics American Depositary Shares?

Is LKFT or OCGN more profitable?

Does the media favor LKFT or OCGN?

Which has more volatility and risk, LKFT or OCGN?

Do analysts prefer LKFT or OCGN?

Which has higher earnings and valuation, LKFT or OCGN?

Do institutionals and insiders hold more shares of LKFT or OCGN?

Summary

How does Ocugen compare to Nurix Therapeutics?

Which has higher earnings and valuation, OCGN or NRIX?

Do analysts prefer OCGN or NRIX?

Do institutionals & insiders have more ownership in OCGN or NRIX?

Does the media prefer OCGN or NRIX?

Is OCGN or NRIX more profitable?

Which has more risk & volatility, OCGN or NRIX?

Summary

How does Ocugen compare to Rapport Therapeutics?

Is OCGN or RAPP more profitable?

Which has higher valuation and earnings, OCGN or RAPP?

Which has more volatility and risk, OCGN or RAPP?

Do insiders & institutionals have more ownership in OCGN or RAPP?

Do analysts rate OCGN or RAPP?

Does the media prefer OCGN or RAPP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN vs. The Competition

Ocugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools